Your Health, We Care
1. Previously Untreated Mantle Cell LymphomaAcalabrutinib (CALQUENCE) in combination with bendamustine and rituximab is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have not received prior treatment and are ineligible for autologous hematopoietic stem cell transplantation (HSCT).
2. Previously Treated Mantle Cell LymphomaAcalabrutinib (CALQUENCE) is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
3. Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaAcalabrutinib (CALQUENCE) is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
FDA，2025.01
